Literature DB >> 14581920

Emergency medicine tools to manage smallpox (vaccinia) vaccination complications: clinical practice guideline and policies and procedures.

Craig D Thorne1, Jon Mark Hirshon, Carrie D Himes, Melissa A McDiarmid.   

Abstract

In December 2002, the federal government began a program to immunize approximately 500000 civilian public health and health care workers with smallpox (vaccinia) vaccine as a part of our pre-event defense against bioterrorism. First responders will likely follow, and the general US population might be offered vaccination in the next 1 to 2 years. Recent reports that suggest the possible association of the vaccine to adverse cardiac events (including deaths), liability concerns for hospitals, and the availability of compensation for workers with vaccine complications have significantly reduced voluntary participation. Vaccinees might experience robust primary takes or serious adverse events, including viral or even bacterial cellulitides, encephalitis, progressive skin destruction, and other life-threatening complications. With the increasing prevalence of immune suppression from both diseases and immunosuppressive medications, complications might be seen in higher frequency than previously reported. Emergency medicine providers and staff must become familiar with clinical presentations and management of vaccine complications. In addition, policies and procedures must be developed to prevent unimmunized providers from inadvertently contacting the active vaccination sites of their patients and, if the providers themselves have active vaccination sites, to protect their patients and their own families.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581920     DOI: 10.1016/s0196-0644(03)00629-2

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  4 in total

Review 1.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

Review 2.  Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.

Authors:  Hajime Sato
Journal:  Environ Health Prev Med       Date:  2010-12-21       Impact factor: 3.674

3.  Use of a recombinant vaccinia virus expressing interferon gamma for post-exposure protection against vaccinia and ectromelia viruses.

Authors:  Susan A Holechek; Karen L Denzler; Michael C Heck; Jill Schriewer; R Mark Buller; Fatema A Legrand; Paulo H Verardi; Leslie A Jones; Tilahun Yilma; Bertram L Jacobs
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

Review 4.  The risks and benefits of pre-event smallpox vaccination: where you stand depends on where you sit.

Authors:  Tomás J Aragón; Susan E Fernyak
Journal:  Ann Emerg Med       Date:  2003-11       Impact factor: 5.721

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.